Scholarlink

<p>Acute myeloid leukemia (AML) is a hematological malignancy characterized by clonal expansion of myeloid progenitors in the bone marrow, resulting in impaired hematopoiesis. AML remains challenging due to frequent disease recurrence and limited treatment alternatives, highlighting the necessity for further research. Corilagin, an ellagitannin isolated from ethnopharmacological plants, displays potential anti-cancer activity, but its anti-leukemic effects and mechanism in AML are unclear. This study aimed to assess whether corilagin induces cell death in AML cells, a cell-derived xenograft (CDX) model, and primary AML cells, and to elucidate its therapeutic mechanism in AML.&#xa0;Cell viability was measured using the Cell Counting Kit-8 and proliferation was assessed with an EdU imaging kit. Flow cytometry analyzed PI-positive cells. Pyroptosis was evaluated by morphology and LDH release. mRNA and protein levels were measured by qPCR and western blot. Stable cell lines with gene knockouts were created using CRISPR-Cas9. The therapeutic efficacy of corilagin was also tested in CDX models.&#xa0;Corilagin treatment induced pyroptotic bubbles in AML cells, increasing LDH release and PI-positive cells. Corilagin activated caspase-3, which cleaved gasdermin E (GSDME) to form active GSDME-NT, promoting pyroptosis. Corilagin also activated thioredoxin-interacting protein (TXNIP), and TXNIP knockdown by siRNA rescued corilagin-induced pyroptosis. Corilagin reduced viability and promoted pyroptosis in primary AML cells. In an AML CDX mouse model, corilagin inhibited leukemia progression and prolonged survival.&#xa0;Our results suggested that corilagin induced pyroptosis in AML by activating the TXNIP/caspase-3/GSDME pathway, offering a potential therapeutic strategy for AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Corilagin induces pyroptosis in AML cells by activating the TXNIP-caspase-3-GSDME pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月11日

查看全文
  • Ganlu Feng,
  • Yizhen Li,
  • Ying Wang,
  • Yue Li,
  • Nianhui Yang,
  • Fangshu Liu,
  • Xiaofan Sun,
  • Kexiu Huang,
  • Danqi Pan,
  • Yingying Wu,
  • Caiping Wu,
  • Weihao Xiao,
  • Xingcheng Liu,
  • Zhuo Lv,
  • Dongfan Wang,
  • Xue Li,
  • Juan Du,
  • Hui Zeng

摘要

Acute myeloid leukemia (AML) is a hematological malignancy characterized by clonal expansion of myeloid progenitors in the bone marrow, resulting in impaired hematopoiesis. AML remains challenging due to frequent disease recurrence and limited treatment alternatives, highlighting the necessity for further research. Corilagin, an ellagitannin isolated from ethnopharmacological plants, displays potential anti-cancer activity, but its anti-leukemic effects and mechanism in AML are unclear. This study aimed to assess whether corilagin induces cell death in AML cells, a cell-derived xenograft (CDX) model, and primary AML cells, and to elucidate its therapeutic mechanism in AML. Cell viability was measured using the Cell Counting Kit-8 and proliferation was assessed with an EdU imaging kit. Flow cytometry analyzed PI-positive cells. Pyroptosis was evaluated by morphology and LDH release. mRNA and protein levels were measured by qPCR and western blot. Stable cell lines with gene knockouts were created using CRISPR-Cas9. The therapeutic efficacy of corilagin was also tested in CDX models. Corilagin treatment induced pyroptotic bubbles in AML cells, increasing LDH release and PI-positive cells. Corilagin activated caspase-3, which cleaved gasdermin E (GSDME) to form active GSDME-NT, promoting pyroptosis. Corilagin also activated thioredoxin-interacting protein (TXNIP), and TXNIP knockdown by siRNA rescued corilagin-induced pyroptosis. Corilagin reduced viability and promoted pyroptosis in primary AML cells. In an AML CDX mouse model, corilagin inhibited leukemia progression and prolonged survival. Our results suggested that corilagin induced pyroptosis in AML by activating the TXNIP/caspase-3/GSDME pathway, offering a potential therapeutic strategy for AML.